Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study

Keith Edwards, Donald Royall, Linda Hershey, David Lichter, Ann Hake, Martin Farlow, Florence Pasquier, Stewart Johnson

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


Background: Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs). Methods: A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB. Results: This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient. Conclusion: Galantamine appears to be an effective and safe therapy for patients with DLB.

Original languageEnglish (US)
Pages (from-to)401-405
Number of pages5
JournalDementia and Geriatric Cognitive Disorders
Issue number6
StatePublished - May 2007


  • Cholinesterase inhibitors
  • Dementia with Lewy bodies
  • Galantamine
  • Visual hallucinations

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cognitive Neuroscience


Dive into the research topics of 'Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study'. Together they form a unique fingerprint.

Cite this